On March 6, 2026, Harvard Bioscience, Inc. updated employment agreements for CEO John Duke and CFO Mark Frost, with Duke receiving a base salary of $515,000 and Frost $375,000, while both are eligible for equity grants of 75,000 and 30,000 units respectively after a reverse stock split.